{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:32:05Z","timestamp":1789723925865,"version":"4.0.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1007\/s00415-009-0097-x","type":"journal-article","created":{"date-parts":[[2009,3,6]],"date-time":"2009-03-06T18:28:02Z","timestamp":1236364082000},"page":"3-12","source":"Crossref","is-referenced-by-count":52,"title":["Cerebrospinal fluid biomarkers in Guillain-Barr\u00e9 syndrome \u2013 Where do we stand?"],"prefix":"10.1007","volume":"256","author":[{"given":"Johannes","family":"Brettschneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Petzold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurd","family":"S\u00fcssmuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,2,16]]},"reference":[{"key":"97_CR1","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.1542\/peds.109.2.e31","volume":"109","author":"Berger","year":"2002","unstructured":"Berger RP, Pierce MC, Wisniewski SR,Adelson PD, Clark RS, Ruppel RA,Kochanek PM (2002) Neuron-specificenolase and S100B in cerebrospinalfluid after severe traumatic brain injuryin infants and children. Pediatrics109:E31","journal-title":"Pediatrics"},{"key":"97_CR2","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1212\/01.wnl.0000249150.98891.d1","volume":"67","author":"Bersano","year":"2006","unstructured":"Bersano A, Fiorini M, Allaria S,Zanusso G, Fasoli E, Gelati M, MonacoH, Squintani G, Monaco S, Nobile-Orazio E (2006) Detection of CSF14-3-3 protein in Guillain-Barr\u00e9syndrome. Neurology 67:2211\u20132216","journal-title":"Neurology"},{"key":"97_CR3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1373\/49.1.7","volume":"49","author":"Bossuyt","year":"2003","unstructured":"Bossuyt PM, Reitsma JB, Bruns DE,Gatsonis CA, Glasziou PP, Irwig LM,Moher D, Rennie D, de Vet HC, LijmerJG (2003) Standards for Reporting ofDiagnostic Accuracy. The STARDstatement for reporting studies ofdiagnostic accuracy: explanation andelaboration. Clin Chem 49:7\u201318","journal-title":"Clin Chem"},{"key":"97_CR4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1042\/bst0080617","volume":"8","author":"Boston","year":"1980","unstructured":"Boston P, Jackson P (1980) Purificationand properties of a brain-specific protein,human 14-3-3 protein. BiochemSoc Trans 8:617\u2013618","journal-title":"BiochemSoc Trans"},{"key":"97_CR5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/ng1201-365","volume":"29","author":"Brazma","year":"2001","unstructured":"Brazma A, Hingamp P, Quackenbush J,Sherlock G, Spellman P, Stoeckert C,Aach J, Ansorge W, Ball CA, CaustonHC, Gaasterland T, Glenisson P, HolstegeFC, Kim IF, Markowitz V, MateseJC, Parkinson H, Robinson A, SarkansU, Schulze-Kremer S, Stewart J, TaylorR, Vilo J, Vingron M (2001) Minimuminformation about a microarray experiment(MIAME)-toward standards formicroarray data. Nat Genet 29:365\u2013371","journal-title":"Nat Genet"},{"key":"97_CR6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00415-005-0817-9","volume":"252","author":"Brettschneider","year":"2005","unstructured":"Brettschneider J, Claus A, Kassubek J,Tumani H (2005) Isolated blood-cerebrospinalfluid barrier dysfunction:prevalence and associated diseases.J Neurol 252:1067\u20131073","journal-title":"J Neurol"},{"key":"97_CR7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000091436","volume":"21","author":"Brettschneider","year":"2006","unstructured":"Brettschneider J, Petzold A, Claus A,Tumani H (2006) The Neurofilamentheavy chain (NfHSMI35) in the cerebrospinalfluid diagnosis of Alzheimerdisease. Dem Geriatr Cogn Disord 21:291\u2013295","journal-title":"Dem Geriatr Cogn Disord"},{"key":"97_CR8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1212\/01.wnl.0000203120.85850.54","volume":"28","author":"Brettschneider","year":"2006","unstructured":"Brettschneider J, Petzold A, SussmuthSD, Ludolph A, Tumani H (2006)Axonal damage markers in cerebrospinalfluid are increased in ALS.Neurology 28:852\u2013856","journal-title":"Neurology"},{"key":"97_CR9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1191\/135248506ms1263oa","volume":"12","author":"Brettschneider","year":"2006","unstructured":"Brettschneider J, Petzold A, Junker A,Tumani H (2006) Axonal damagemarkers in cerebrospinal fluid ofpatients with clinically isolated syndromeimprove predicting conversionto definite MS. Mult Scler 12:143\u2013148","journal-title":"Mult Scler"},{"key":"97_CR10","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1212\/01.WNL.0000055091.96905.D0","volume":"60","author":"Chi\u00f2","year":"2003","unstructured":"Chi\u00f2 A, Cocito D, Leone M, GiordanaMT, Mora G, Mutani R; Piemonte andValle d\u2019Aosta Register for Guillain-Barr\u00e9 Syndrome (2003) Guillain-Barr\u00e9syndrome: a prospective, population-basedincidence and outcome survey.Neurology 60:1146\u20131150","journal-title":"Neurology"},{"key":"97_CR11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0022-510X(91)90303-O","volume":"104","author":"De Jager","year":"1991","unstructured":"De Jager AE, Sluiter HJ (1991) Clinicalsigns in severe Guillain-Barr\u00e9syndrome: analysis of 63 patients.J Neurol Sci 104:143\u2013150","journal-title":"J Neurol Sci"},{"key":"97_CR12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/003693307201700106","volume":"17","author":"Dunn","year":"1972","unstructured":"Dunn JS, Wyburn GM (1972) Theanatomy of the blood brain barrier:a review. Scott Med J 17:21\u201336","journal-title":"Scott Med J"},{"key":"97_CR13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0022-3476(75)80962-0","volume":"86","author":"Eberle","year":"1975","unstructured":"Eberle E, Brink J, Azen S, White D(1975) Early predictors of incompleterecovery in children with Guillain-Barr\u00e9 polyneuritis. J Pediatr 86:356\u2013359","journal-title":"J Pediatr"},{"key":"97_CR14","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1523\/JNEUROSCI.04-12-03101.1984","volume":"4","author":"Gibson","year":"1984","unstructured":"Gibson SJ, Polak JM, Bloom SR, SabateIM, Mulderry PM, Ghatei MA,McGregor GP, Morrison JF, Kelly JS,Evans RM (1984) Calcitonin gene-relatedpeptide immunoreactivity inthe spinal cord of man and of eightother species. J Neurosci 4:3101\u20133111","journal-title":"J Neurosci"},{"key":"97_CR15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/118.3.577","volume":"118","author":"Griffin","year":"1995","unstructured":"Griffin JW, Li CY, Ho TW, Xue P, MackoC, Gao CY, Yang C, Tian M, Mishu B,Cornblath DR (1995) Guillain-Barr\u00e9syndrome in northern China. Thespectrum of neuropathologicalchanges in clinically defined cases.Brain 118:577\u2013595","journal-title":"Brain"},{"key":"97_CR16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF02284784","volume":"25","author":"Griffin","year":"1996","unstructured":"Griffin JW, Li CY, Macko C, Ho TW,Hsieh ST, Xue P, Wang FA, CornblathDR, McKhann GM, Asbury AK (1996)Early nodal changes in the acute motoraxonal neuropathy pattern of theGuillain-Barr\u00e9 syndrome. J Neurocytol25:33\u201351","journal-title":"J Neurocytol"},{"key":"97_CR17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2106\/00004623-197759020-00010","volume":"59","author":"Gordon","year":"1977","unstructured":"Gordon SL, Morris WT , Stoner MA,Greer RB (1977) Residua of Guillain-Barr\u00e9 Polyneuritis in Children. J BoneJoint Surg Am 59:193\u2013197","journal-title":"J BoneJoint Surg Am"},{"key":"97_CR18","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archneur.58.6.913","volume":"58","author":"Gordon","year":"2001","unstructured":"Gordon PH, Wilbourn AJ (2001) Earlyelectrodiagnostic findings in Guillain-Barr\u00e9 syndrome. Arch Neurol 58:913\u2013917","journal-title":"Arch Neurol"},{"key":"97_CR19","first-page":"1462","volume":"40","author":"Guillain","year":"1916","unstructured":"Guillain G, Barr\u00e9 JA, Strohl A (1916)Sur un syndrome de radiculon\u00e9vriteavec hyperalbuminose du liquidec\u00e9phalo-rachidien sans r\u00e9action cellulaire.Remarques sur les caract\u00e8res cliniqueset graphiques des r\u00e9flexes tendineux.Bull Soc M\u00e9d H\u00f4p Paris40:1462\u20131470","journal-title":"Bull Soc M\u00e9d H\u00f4p Paris"},{"key":"97_CR20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.410440512","volume":"44","author":"Hadden","year":"1998","unstructured":"Hadden RD, Cornblath DR, HughesRA, Zielasek J, Hartung HP, Toyka KV,Swan AV (1998) Electrophysiologicalclassification of Guillain-Barr\u00e9 syndrome:clinical associations and outcome.Plasma Exchange\/SandoglobulinGuillain-Barr\u00e9 Syndrome TrialGroup. Ann Neurol 44:780\u2013788","journal-title":"Ann Neurol"},{"key":"97_CR21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ana.410400414","volume":"40","author":"Hafer-Macko","year":"1996","unstructured":"Hafer-Macko C, Hsieh ST, Li CY, HoTW, Sheikh K, Cornblath DR,McKhann GM, Asbury AK, Griffin JW(1996) Acute motor axonal neuro pathy:an antibody-mediated attack onaxolemma. Ann Neurol 40:635\u2013644","journal-title":"Ann Neurol"},{"key":"97_CR22","first-page":"552","volume":"93","author":"Hart","year":"1972","unstructured":"Hart MN, Hanks DT, Mackay R (1972)Ultrastructural observations in Guillain-Barr\u00e9 syndrome. Arch Pathol 93:552\u2013555","journal-title":"Arch Pathol"},{"key":"97_CR23","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.37.6.1006","volume":"37","author":"Hartung","year":"1987","unstructured":"Hartung HP, Schwenke C, Bitter-Suermann D, Toyka KV (1987)Guillain-Barr\u00e9 syndrome: activatedcomplement components C3a and C5ain CSF. Neurology 37:1006\u20131009","journal-title":"Neurology"},{"key":"97_CR24","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/brain\/114.3.1245","volume":"114","author":"Honavar","year":"1991","unstructured":"Honavar M, Tharakan JK, Hughes RA,Leibowitz S, Winer JB (1991) A clinico-pathologicalstudy of the Guillain-Barr\u00e9 syndrome. Nine cases and literaturereview. Brain114:1245\u20131269","journal-title":"Brain"},{"key":"97_CR25","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","volume":"3","author":"Hughes","year":"2005","unstructured":"Hughes RA, Cornblath DR (2005)Guillain-Barr\u00e9 syndrome. Lancet3:1653\u20131666","journal-title":"Lancet"},{"key":"97_CR26","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","volume":"2","author":"Hughes","year":"1978","unstructured":"Hughes RA, Newsom-Davies JM,Perkins GD (1978) Controlled trial ofprednisolone in acute polyneuropathy.Lancet 2:750\u2013753","journal-title":"Lancet"},{"key":"97_CR27","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1468-1331.2007.01761.x","volume":"14","author":"Jin","year":"2007","unstructured":"Jin T, Hu LS, Chang M, Wu J, WinbladB, Zhu J (2007) Proteomic identificationof potential protein markers incerebrospinal fluid of GBS patients.Eur J Neurol 14:563\u2013568","journal-title":"Eur J Neurol"},{"key":"97_CR28","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1212\/01.wnl.0000240119.29939.c7","volume":"67","author":"Jin","year":"2006","unstructured":"Jin K, Takeda A, Shiga Y, Sato S,Ohnuma A, Nomura H, Arai H,Kusunoki S, Ikeda M, Itoyama Y (2006)CSF tau protein: a new prognosticmarker for Guillain-Barr\u00e9 syndrome.Neurology 67:1470\u20131472","journal-title":"Neurology"},{"key":"97_CR29","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/ana.20222","volume":"56","author":"Kaida","year":"2004","unstructured":"Kaida K, Morita D, Kanzaki M, KamakuraK, Motoyoshi K, Hirakawa M,Kusunoki S (2004) Ganglioside complexesas new target antigens in Guillain-Barr\u00e9 syndrome. Ann Neurol 56:567\u2013571","journal-title":"Ann Neurol"},{"key":"97_CR30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0165-5728(03)00085-7","volume":"137","author":"Kastenbauer","year":"2003","unstructured":"Kastenbauer S, Koedel U, Wick M,Kieseier BC, Hartung HP, Pfister HW(2003) CSF and serum levels of solublefractalkine (CX3CL1) in inflammatorydiseases of the nervous system. J Neuroimmunol137:210\u2013217","journal-title":"J Neuroimmunol"},{"key":"97_CR31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mus.20076","volume":"30","author":"Kieseier","year":"2004","unstructured":"Kieseier BC, Kiefer R, Gold R, HemmerB, Willison HJ, Hartung HP (2004)Advances in understanding and treatmentof immune-mediated disordersof the peripheral nervous system.Muscle Nerve 30:131\u2013156","journal-title":"Muscle Nerve"},{"key":"97_CR32","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/brain\/awf070","volume":"125","author":"Kieseier","year":"2002","unstructured":"Kieseier BC, Tani M, Mahad D, Oka N,Ho T, Woodroofe N, Griffin JW, ToykaKV, Ransohoff RM, Hartung HP (2002)Chemokines and chemokine receptorsin inflammatory demyelinating neuropathies:a central role for IP-10.Brain 125:823\u2013834","journal-title":"Brain"},{"key":"97_CR33","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"Kleyweg","year":"1999","unstructured":"Kleyweg RP, van der Meche FG,Schmitz PI (1999) Interobserveragreement in the assessment of musclestrength and functional abilities inGuillain-Barr\u00e9 syndrome. MuscleNerve 14:1103\u20131109","journal-title":"Muscle Nerve"},{"key":"97_CR34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-0404.1995.tb05844.x","volume":"91","author":"Koguchi","year":"1995","unstructured":"Koguchi Y, Yamada T, Kuwabara S,Nakajima M, Hirayama K (1995)Increased CSF C4d in demyelinatingneuropathy indicates the radicularinvolvement. Acta Neurol Scand 91:58\u201361","journal-title":"Acta Neurol Scand"},{"key":"97_CR35","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.82.3.905","volume":"82","author":"Koski","year":"1985","unstructured":"Koski CL, Humphrey R, Shin ML(1985) Anti-peripheral myelin antibodyin patients with demyelinatingneuropathy: quantitative and kineticdetermination of serum antibody bycomplement component 1 fixation.Proc Natl Acad Sci USA 82:905\u2013909","journal-title":"Proc Natl Acad Sci USA"},{"key":"97_CR36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00313314","volume":"226","author":"Kr\u00fcger","year":"1981","unstructured":"Kr\u00fcger H, Englert D, Pflughaupt KW(1981) Demonstration of oligoclonalimmunoglobulin G in Guillain-Barr\u00e9syndrome and lymphocytic meningoradiculitisby isoelectric focusing.J Neurol 226:15\u201324","journal-title":"J Neurol"},{"key":"97_CR37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jneuroim.2007.01.022","volume":"185","author":"Lehmensiek","year":"2007","unstructured":"Lehmensiek V, S\u00fcssmuth SD, BrettschneiderJ, Tauscher G, Felk S,Gillardon F, Tumani H (2007) Proteomeanalysis of cerebrospinal fluidin Guillain-Barr\u00e9 syndrome (GBS).J Neuroimmunol 185:190\u2013194","journal-title":"J Neuroimmunol"},{"key":"97_CR38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/jnnp.63.4.494","volume":"63","author":"Lyu","year":"1997","unstructured":"Lyu RK, Tang LM, Cheng SY, Hsu WC,Chen ST (1997) Guillain-Barr\u00e9 syndromein Taiwan: a clinical study of167 patients. J Neurol NeurosurgPsychiatry 63:494\u2013500","journal-title":"J Neurol NeurosurgPsychiatry"},{"key":"97_CR39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-5728(93)90284-6","volume":"47","author":"Maimone","year":"1993","unstructured":"Maimone D, Annunziata P, Simone IL,Livrea P, Guazzi GC (1993) Interleukin-6 levels in the cerebrospinal fluidand serum of patients with Guillain-Barr\u00e9 syndrome and chronic inflammatorydemyelinating polyradiculoneuropathy.J Neuroimmunol 47:55\u201361","journal-title":"J Neuroimmunol"},{"key":"97_CR40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1590\/S0004-282X1990000400010","volume":"48","author":"Marchiori","year":"1990","unstructured":"Marchiori PE, Dos Reis M, QuevedoME, Callegaro D, Hirata MT, Scaff M,De Oliveira RM (1990) Cerebrospinalfluid and serum antiphospholipid antibodiesin multiple sclerosis, Guillain-Barr\u00e9 syndrome and systemic lupuserythematosus. Arq Neuropsiquiatr48:465\u2013468","journal-title":"Arq Neuropsiquiatr"},{"key":"97_CR41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1468-1331.2006.01161.x","volume":"13","author":"Mat\u00e0","year":"2006","unstructured":"Mat\u00e0 S, Galli E, Amantini A, Pinto F,Sorbi S, Lolli F (2006) Anti-gangliosideantibodies and elevated CSF IgG levelsin Guillain-Barr\u00e9 syndrome. Eur JNeurol 13:153\u2013160","journal-title":"Eur JNeurol"},{"key":"97_CR42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","volume":"93","author":"McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W,Taube SE, Gion M, Clark GM; StatisticsSubcommittee of the NCI-EORTCWorking Group on Cancer Diagnostics(2005) REporting recommendationsfor tumour MARKer prognostic studies(REMARK). Br J Cancer 93:387\u2013391","journal-title":"Br J Cancer"},{"key":"97_CR43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1212\/WNL.59.1.84","volume":"59","author":"Merkies","year":"2002","unstructured":"Merkies IS, Schmitz P, van der MecheFG, Samijn JP, van Doorn PA (2002)Quality of life complements traditionaloutcome measures in immune-mediatedpolyneuropathies. Neurology 59:84\u201391","journal-title":"Neurology"},{"key":"97_CR44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0404.1994.tb01628.x","volume":"89","author":"Mokuno","year":"1994","unstructured":"Mokuno K, Kiyosawa K, Sugimura K,Yasuda T, Riku S, Murayama T, YanagiT, Takahashi A, Kato K (1994) Prognosticvalue of cerebrospinal fluid neuronspecificenolase and S-100b protein inGuillain-Barr\u00e9 syndrome. Acta NeurolScand 89:27\u201330","journal-title":"Acta NeurolScand"},{"key":"97_CR45","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1212\/WNL.55.12.1828","volume":"55","author":"Nagai","year":"2000","unstructured":"Nagai A, Murakawa Y, Terashima M,Shimode K, Umegae N, Takeuchi H,Kobayashi S (2000) Cystatin C andcathepsin B in CSF from patients withinflammatory neurologic diseases.Neurology 55:1828\u20131832","journal-title":"Neurology"},{"key":"97_CR46","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1212\/01.WNL.0000081049.14098.50","volume":"61","author":"Nishino","year":"2003","unstructured":"Nishino S, Kanbayashi T, Fujiki N,Uchino M, Ripley B, Watanabe M,Lammers GJ, Ishiguro H, Shoji S,Nishida Y, Overeem S, Toyoshima I,Yoshida Y, Shimizu T, Taheri S, MignotE (2003) CSF hypocretin levels inGuillain-Barr\u00e9 syndrome and otherinflammatory neuropathies. Neurology61:823\u2013825","journal-title":"Neurology"},{"key":"97_CR47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1468-1331.2000.00005.x","volume":"7","author":"Ossege","year":"2000","unstructured":"Ossege LM, Sindern E, Voss B, Malin JP(2000) Expression of TNFalpha andTGFbeta1 in Guillain-Barr\u00e9 syndrome:correlation of a low TNFalpha-\/TGF-beta1-mRNA ratio with good recoveryand signs for immunoregulationwithin the cerebrospinal fluid compartment.Eur J Neurol 7:17\u201325","journal-title":"Eur J Neurol"},{"key":"97_CR48","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s004150050145","volume":"244","author":"Otto","year":"1997","unstructured":"Otto M, Stein H, Szudra A, Zerr I,Bodemer M, Gefeller O, Poser S,Kretzschmar HA, Mader M, Weber T(1997) S-100 protein concentration inthe cerebrospinal fluid of patients withCreutzfeldt-Jakob disease. J Neurol244:566\u2013570","journal-title":"J Neurol"},{"key":"97_CR49","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s004150050290","volume":"245","author":"Patzold","year":"1998","unstructured":"Patzold T, Sindern E, Ossege-Pohle L,Malin JP (1998) The soluble 60-kDatumour necrosis factor receptor: nodifference found between patients withrelapsing-remitting multiple sclerosisand controls: increasing levels are associatedwith the recovery fromGuillain-Barr\u00e9 syndrome. J Neurol245:803\u2013808","journal-title":"J Neurol"},{"key":"97_CR50","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/jnnp.2004.043315","volume":"76","author":"Petzold","year":"2005","unstructured":"Petzold A, Eikelenboom MJ, Keir G,Grant D, Lazeron RH, Polman CH,Uitdehaag BM, Thompson EJ, GiovannoniG (2005) Axonal damage accumulatesin the progressive phase of multiplesclerosis: three year follow upstudy. J Neurol Neurosurg Psychiatry76:206\u2013211","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"97_CR51","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1212\/01.wnl.0000237334.69665.92","volume":"67","author":"Petzold","year":"2006","unstructured":"Petzold A, Hinds N, Murray NM,Hirsch NP, Grant D, Keir G, ThompsonEJ, Reilly MM (2006) CSF neurofilamentlevels: a potential prognosticmarker in Guillain-Barr\u00e9 syndrome.Neurology 67:1071\u20131073","journal-title":"Neurology"},{"key":"97_CR52","first-page":"179","volume":"278","author":"Petzold","year":"2003","unstructured":"Petzold A, Keir G, Green AJ, GiovannoniG, Thompson EJ (2003) A specificELISA for measuring neurofilamentheavy chain phosphoforms. J ImmunolMethods 278:179\u2013190","journal-title":"J ImmunolMethods"},{"key":"97_CR53","first-page":"34","volume":"319","author":"Petzold","year":"2007","unstructured":"Petzold A, Shaw G (2007) Comparisonof two ELISA methods for measuringlevels of the phosphorylated neurofilamentheavy chain. J Immunol Methods319:34\u201340","journal-title":"J ImmunolMethods"},{"key":"97_CR54","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1024532715775","volume":"23","author":"Press","year":"2003","unstructured":"Press R, Pashenkov M, Jin JP, Link H(2003) Aberrated levels of cerebrospinalfluid chemokines in Guillain-Barr\u00e9syndrome and chronic inflammatorydemyelinating polyradiculoneuropathy.J Clin Immunol 23:259\u2013267","journal-title":"J Clin Immunol"},{"key":"97_CR55","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ana.410090704","volume":"9","author":"Prineas","year":"1981","unstructured":"Prineas JW (1981) Pathology of theGuillain-Barr\u00e9 syndrome. Ann Neurol9(Suppl):6\u201319","journal-title":"Ann Neurol"},{"key":"97_CR56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1468-1331.2003.00644.x","volume":"10","author":"Rauschka","year":"2003","unstructured":"Rauschka H, Jellinger K, Lassmann H,Braier F, Schmidbauer M (2003) Guillain-Barr\u00e9 syndrome with markedpleocytosis or a significant proportionof polymorphonuclear granulocytes inthe cerebrospinal fluid: neuropathologicalinvestigation of five cases andreview of differential diagnoses. Eur JNeurol 10:479\u2013486","journal-title":"Eur JNeurol"},{"key":"97_CR57","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJM199511233332102","volume":"333","author":"Rees","year":"1995","unstructured":"Rees JH, Soudain SE, Gregson NA,Hughes RA (1995) Campylobacterjejuni infection and Guillain-Barr\u00e9syndrome. N Engl J Med 333:1374\u20131379","journal-title":"N Engl J Med"},{"key":"97_CR58","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/135245859800400304","volume":"4","author":"Reiber","year":"1998","unstructured":"Reiber H (1998) Cerebrospinal fluid \u2013physiology, analysis and interpretationof protein patterns for diagnosis ofneurological diseases. Mult Scler4:99\u2013107","journal-title":"Mult Scler"},{"key":"97_CR59","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1212\/WNL.57.12.2253","volume":"57","author":"Ripley","year":"2001","unstructured":"Ripley B, Overeem S, Fujiki N,Nevsimalova S, Uchino M, Yesavage J,Di Monte D, Dohi K, Melberg A,Lammers GJ, Nishida Y, Roelandse FW,Hungs M, Mignot E, Nishino S (2001)CSF hypocretin\/orexin levels in narcolepsyand other neurological conditions.Neurology 57:2253\u20132258","journal-title":"Neurology"},{"key":"97_CR60","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1046\/j.1471-4159.1996.67052013.x","volume":"67","author":"Rosengren","year":"1996","unstructured":"Rosengren LE, Karlsson JE, KarlssonJO, Persson LI, Wikkelso C (1996)Patients with amyotrophic lateralsclerosis and other neurodegenerativediseases have increased levels of neurofilamentprotein in CSF. J Neurochem67:2013\u20132018","journal-title":"J Neurochem"},{"key":"97_CR61","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.4049\/jimmunol.136.12.4456","volume":"136","author":"Sanders","year":"1986","unstructured":"Sanders ME, Koski CL, Robbins D, ShinML, Frank MM, Joiner KA (1986) Activatedterminal complement in cerebrospinalfluid in Guillain-Barr\u00e9syndrome and multiple sclerosis.J Immunol 136:4456\u20134459","journal-title":"J Immunol"},{"key":"97_CR62","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000008054","volume":"41","author":"Satoh","year":"1999","unstructured":"Satoh J, Kurohara K, Yukitake M,Kuroda Y (1999) The 14-3-3 proteindetectable in the cerebrospinal fluid ofpatients with prion-unrelated neurologicaldiseases is expressed constitutivelyin neurons and glial cells inculture. Eur Neurol 41:216\u2013225","journal-title":"Eur Neurol"},{"key":"97_CR63","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/BF00314019","volume":"233","author":"Segurado","year":"1986","unstructured":"Segurado OG, Kr\u00fcger H, Mertens HG(1986) Clinical significance of serumand CSF findings in the Guillain-Barr\u00e9syndrome and related disorders.J Neurol 233:202\u2013208","journal-title":"J Neurol"},{"key":"97_CR64","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1749-6632.1998.tb09683.x","volume":"845","author":"Sheikh","year":"1998","unstructured":"Sheikh KA, Ho TW, Nachamkin I, LiCY, Cornblath DR, Asbury AK, GriffinJW, McKhann GM (1998) Molecularmimicry in Guillain-Barr\u00e9 syndrome.Ann N Y Acad Sci 845:307\u2013321","journal-title":"Ann N Y Acad Sci"},{"key":"97_CR65","first-page":"49","volume":"114","author":"Simone","year":"1993","unstructured":"Simone IL, Annunziata P, Maimone D,Liguori M, Leante R, Livrea P (1993)Serum and CSF anti-GM1 antibodiesin patients with Guillain-Barr\u00e9 syndromeand chronic inflammatory demyelinatingpolyneuropathy. J NeurolSci 114:49\u201355","journal-title":"J NeurolSci"},{"key":"97_CR66","first-page":"777","volume":"42","author":"Singh","year":"1994","unstructured":"Singh NK, Jaiswal AK, Misra S, SrivastavaPK (1994) Prognostic factors inGuillain-Barr\u00e9 syndrome. J AssocPhysicians India 42:777\u2013779","journal-title":"J AssocPhysicians India"},{"key":"97_CR67","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0022-510X(96)00319-X","volume":"147","author":"Sivieri","year":"1997","unstructured":"Sivieri S, Ferrarini AM, Lolli F, Mat\u00e0 S,Pinto F, Tavolato B, Gallo P (1997)Cytokine pattern in the cerebrospinalfluid from patients with GBS and CIDP.J Neurol Sci 147:93\u201395","journal-title":"J Neurol Sci"},{"key":"97_CR68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00002517-199407010-00002","volume":"7","author":"Skouen","year":"1994","unstructured":"Skouen JS, Larsen JL, Vollset SE (1994)Cerebrospinal fluid protein concentrationsrelated to clinical findings in patientswith sciatica caused by diskherniation. J Spinal Disord 7:12\u201318","journal-title":"J Spinal Disord"},{"key":"97_CR69","first-page":"95","volume":"300","author":"S\u00fcssmuth","year":"2001","unstructured":"S\u00fcssmuth SD, Reiber H, Tumani H(2001) Tau protein in cerebrospinalfluid (CSF): a blood-CSF barrier relatedevaluation in patients with variousneurological diseases. NeurosciLett 300:95\u201398","journal-title":"NeurosciLett"},{"key":"97_CR70","first-page":"133","volume":"45","author":"Van der Meche","year":"2001","unstructured":"Van der Meche FGA, Van Doorn PA,Meulstee J, Jennekens FGI (2001)Diagnostic and classification criteriafor the Guillain-Barr\u00e9 syndrome. EurNeurol 45:133\u2013139","journal-title":"EurNeurol"},{"key":"97_CR71","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jim.2004.11.015","volume":"296","author":"Van Geel","year":"2005","unstructured":"Van Geel WJA, Rosengren LE, andVerbeek MM (2005) An enzymeimmunoassay to quantify neurofilamentlight chain in cerebrospinal fluid.J Immunol Meth 296:179\u2013185","journal-title":"J Immunol Meth"},{"key":"97_CR72","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1073\/pnas.79.10.3290","volume":"79","author":"Vanguri","year":"1982","unstructured":"Vanguri P, Koski CL, Silverman B, ShinML (1982) Complement activation byisolated myelin: activation of the classicalpathway in the absence of myelin-specificantibodies. Proc Natl Acad SciUSA 79:3290\u20133294","journal-title":"Proc Natl Acad SciUSA"},{"key":"97_CR73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0009-8981(90)90332-M","volume":"187","author":"Vermuyten","year":"1990","unstructured":"Vermuyten K, Lowenthal A, Karcher D(1990) Detection of neuron specificenolase concentrations in cerebrospinalfluid from patients with neurologicaldisorders by means of a sensitiveenzyme immunoassay. Clin Chim Acta187:69\u201378","journal-title":"Clin Chim Acta"},{"key":"97_CR74","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1212\/WNL.53.3.598","volume":"53","author":"Visser","year":"1999","unstructured":"Visser LH, Schmitz PI, Meulstee J, vanDoorn PA, van der Meche FG (1999)Prognostic factors of Guillain-Barr\u00e9syndrome after intravenous immunoglobulinor plasma exchange. DutchGuillain-Barr\u00e9 Study Group. Neurology53:598\u2013604","journal-title":"Neurology"},{"key":"97_CR75","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0022-510X(91)90313-V","volume":"104","author":"Weller","year":"1991","unstructured":"Weller M, Stevens A, Sommer N,Melms A, Dichgans J, Wieth\u00f6lter H(1991) Comparative analysis ofcytokine patterns in immunological,infectious, and oncological neurologicaldisorders. J Neurol Sci 104:215\u2013221","journal-title":"J Neurol Sci"},{"key":"97_CR76","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/brain\/awf272","volume":"125","author":"Willison","year":"2002","unstructured":"Willison HJ, Yuki N (2002) Peripheralneuropathies and anti-glycolipid antibodies.Brain 125:2591\u20132625","journal-title":"Brain"},{"key":"97_CR77","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/pmic.200500856","volume":"6","author":"Wilkins","year":"2006","unstructured":"Wilkins MR, Appel RD, Van Eyk JE,Chung MC, G\u00f6rg A, Hecker M, HuberLA, Langen H, Link AJ, Paik YK, PattersonSD, Pennington SR, Rabilloud T,Simpson RJ, Weiss W, Dunn MJ (2006)Guidelines for the next 10 years ofproteomics. Proteomics 6:4\u20138","journal-title":"Proteomics"},{"key":"97_CR78","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1136\/jnnp.51.5.605","volume":"51","author":"Winer","year":"1988","unstructured":"Winer JB, Hughes RA, Ormond C(1988) A prospective study of acuteidiopathic neuropathy. I. Clinicalfeatures and their prognostic value.J Neurol Neurosurg Psychiatry 51:605\u2013612","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"97_CR79","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/cm.20184","volume":"64","author":"Yan","year":"2007","unstructured":"Yan Y, Jensen K, Brown A (2007) Thepolypeptide composition of movingand stationary neurofilaments incultured sympathetic neurons. CellMotil Cytoskeleton 64(4):299\u2013309","journal-title":"CellMotil Cytoskeleton"},{"key":"97_CR80","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1529-8027.2007.00153.x","volume":"12","author":"Yuki","year":"2007","unstructured":"Yuki N, Kuwabara S (2007) AxonalGuillain-Barr\u00e9 syndrome: carbohydratemimicry and pathophysiology.J Peripher Nerv Syst 12:238\u2013249","journal-title":"J Peripher Nerv Syst"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-009-0097-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-009-0097-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-009-0097-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T08:22:05Z","timestamp":1684916525000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-009-0097-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["97"],"URL":"https:\/\/doi.org\/10.1007\/s00415-009-0097-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}